<PAGE> 1
As filed with the Securities and Exchange Commission on June 3, 1997
Registration Statement No. 333-___
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM S-3
----------------------
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
----------------------
HYBRIDON, INC.
(Exact name of registrant as specified in its charter)
----------------------
DELAWARE 04-3072298
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
620 MEMORIAL DRIVE
CAMBRIDGE, MASSACHUSETTS 02139
(617) 528-7000
(Address, including zip code, and
telephone number, including area code,
of registrant's principal
executive offices)
----------------------
E. ANDREWS GRINSTEAD, III
CHAIRMAN OF THE BOARD, PRESIDENT AND CHIEF EXECUTIVE OFFICER
HYBRIDON, INC.
620 MEMORIAL DRIVE
CAMBRIDGE, MASSACHUSETTS 02139
(617) 528-7000
(Name, address, including zip code, and
telephone number, including area code,
of agent for service)
COPY TO:
DAVID E. REDLICK, ESQ.
HALE AND DORR LLP
60 STATE STREET
BOSTON, MASSACHUSETTS 02109
(617) 526-6000
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO PUBLIC: FROM TIME TO
TIME AFTER THIS REGISTRATION STATEMENT BECOMES EFFECTIVE, AS DETERMINED BY THE
REGISTRANT.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
<PAGE> 2
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, check the following box. |X|
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ] 333-_______.
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ] 333-__________.
If delivery of the Prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
--------------------------
<TABLE>
CALCULATION OF REGISTRATION FEE
<CAPTION>
===============================================================================================
Proposed Proposed
Title of Each Class of Amount Maximum Maximum
Securities to be Registered to be Offering Price Aggregate Amount of
Registered Per Share Offering Price Registration Fee
- -----------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock, $.001 par value
per share 5,000,000 $6.50(1) $32,500,000(1) $9,849
- -----------------------------------------------------------------------------------------------
</TABLE>
(1) Estimated solely for purposes of calculating the registration fee pursuant
to Rule 457(c) under the Securities Act and based upon the average of the
high and low prices on the Nasdaq National Market on June 2, 1997.
--------------------------
THE COMPANY HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE COMPANY SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a),
SHALL DETERMINE.
================================================================================
<PAGE> 3
Information contained herein is subject to completion or amendment. A
registration statement relating to these securities has been filed with the
Securities and Exchange Commission. These securities may not be sold nor may
offers to buy be accepted pursuant to this Prospectus prior to the time the
registration statement becomes effective. This Prospectus shall not constitute
an offer to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any State in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities
laws of any such State.
SUBJECT TO COMPLETION, DATED JUNE 3, 1997
PROSPECTUS
HYBRIDON, INC.
5,000,000 SHARES OF COMMON STOCK
---------------------
All of the shares (the "Shares") of Common Stock, par value $.001 per share
("Common Stock"), of Hybridon, Inc., a Delaware corporation ("Hybridon" or the
"Company"), offered hereby are being offered for sale by Hybridon from time to
time.
The Shares will be sold at prices and on terms to be determined at the time
of a sale or sales. The Shares may be sold on a negotiated or competitive bid
basis to or through underwriters or dealers designated from time to time. In
addition, the Shares may be sold by Hybridon to other purchasers directly or
through agents. Certain terms of the sale of the Shares in respect of which this
Prospectus is being delivered, including, where applicable, the names of the
underwriters, dealers and agents, the public offering price, the proceeds to
Hybridon from such sale, and any applicable commissions, discounts and other
terms constituting compensation to such underwriters, dealers or agents, will be
set forth in a Prospectus Supplement, to the extent required (the "Prospectus
Supplement"). See "Plan of Distribution".
The Company's Common Stock is traded on the Nasdaq National Market under
the symbol "HYBN." On June 2, 1997, the closing sale price of the Common Stock
on the Nasdaq National Market was $6.50 per share.
----------------------
THE SECURITIES OFFERED HEREBY INVOLVE A HIGH DEGREE OF RISK.
SEE "RISK FACTORS" BEGINNING ON PAGE 4.
----------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES
COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR
ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY
OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO
THE CONTRARY IS A CRIMINAL OFFENSE.
---------------------
The date of this Prospectus is June ___, 1997.
<PAGE> 4
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information may be inspected and copied at the public
reference facilities maintained by the Commission at 450 Fifth Street, N.W.,
Room 1024, Washington, D.C. 20549 and at the Commission's regional offices
located at Seven World Trade Center, Suite 1300, New York, New York 10048, and
at Citicorp Center, 500 West Madison Street, Suite 1400, Chicago, Illinois
60661. Copies of such materials also may be obtained from the Public Reference
Section of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549 at
prescribed rates. In addition, the Company is required to file electronic
versions of these documents through the Commission's Electronic Data Gathering,
Analysis and Retrieval system (EDGAR). The Commission maintains a World Wide Web
site at http://www.sec.gov that contains reports, proxy and information
statements and other information regarding registrants that file electronically
with the Commission.
The Company has filed with the Commission a Registration Statement on Form
S-3 (together with all amendments, supplements, exhibits and schedules thereto,
the "Registration Statement") under the Securities Act, with respect to the
Shares offered hereby. This Prospectus does not contain all of the information
set forth in the Registration Statement, as certain items are omitted in
accordance with the rules and regulations of the Commission. For further
information pertaining to the Company and the Shares, reference is made to such
Registration Statement. Statements contained in this Prospectus or in any
document incorporated herein by reference regarding the contents of any
agreement or other document are not necessarily complete, and in each instance
reference is made to the copy of such agreement or document filed as an exhibit
to the Registration Statement or such other document, each such statement being
qualified in all respects by such reference. The Registration Statement may be
inspected without charge at the office of the Commission at 450 Fifth Street,
N.W., Washington, D.C. 20549, and copies of all or any part thereof may be
obtained from the Commission at prescribed rates.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by the Company with the Commission are
incorporated herein by reference:
(i) The Company's Annual Report on Form 10-K for the year ended
December 31, 1996, filed with the Commission on March 31, 1997
(the "Form 10-K");
(ii) The Company's Current Report on Form 8-K dated April 2, 1997,
filed with the Commission on April 14, 1997;
(iii) The Company's Proxy Statement for the Annual Meeting of
Stockholders held on May 19, 1997, filed with the Commission
on April 24, 1997;
(iv) The Company's Quarterly Report on Form 10-Q for the quarter
ended March 31, 1997, filed with the Commission on May 15,
1997; and
(v) The Company's Registration Statement on Form 8-A, filed with
the Commission on December 8, 1995.
-2-
<PAGE> 5
All documents filed by the Company with the Commission pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date hereof and
prior to the termination of the offering of the Securities registered hereby
shall be deemed to be incorporated by reference into this Prospectus and to be a
part hereof from the date of filing such documents. Any statement contained in a
document incorporated or deemed to be incorporated by reference herein shall be
deemed to be modified or superseded for purposes of this Prospectus to the
extent that a statement contained herein or in any other subsequently filed
document which also is or is deemed to be incorporated by reference herein
modifies or supersedes such statement. Any statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part
of this Prospectus.
The Company will provide without charge to each person to whom this
Prospectus is delivered, upon written or oral request of such person, a copy of
any or all of the foregoing documents incorporated by reference into this
Prospectus (without exhibits to such documents other than exhibits specifically
incorporated by reference into such documents). All such requests shall be
directed to: Hybridon, Inc., 620 Memorial Drive, Cambridge, Massachusetts 02139,
Attention: Investor Relations Department, Telephone: (617) 528-7000.
NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY
REPRESENTATIONS OTHER THAN THOSE CONTAINED OR INCORPORATED BY REFERENCE IN THIS
PROSPECTUS OR IN ANY APPLICABLE PROSPECTUS SUPPLEMENT AND, IF GIVEN OR MADE,
SUCH OTHER INFORMATION AND REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING
BEEN AUTHORIZED BY THE COMPANY. NEITHER THE DELIVERY OF THIS PROSPECTUS OR ANY
APPLICABLE PROSPECTUS SUPPLEMENT NOR ANY SALE MADE UNDER THIS PROSPECTUS AND ANY
APPLICABLE PROSPECTUS SUPPLEMENT SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY
IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE
THE DATE HEREOF AND THEREOF OR THAT THE INFORMATION CONTAINED IN THIS PROSPECTUS
OR ANY APPLICABLE PROSPECTUS SUPPLEMENT IS CORRECT AS OF ANY TIME SUBSEQUENT TO
THEIR RESPECTIVE DATES. THIS PROSPECTUS AND ANY APPLICABLE PROSPECTUS SUPPLEMENT
DO NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY
SECURITIES OTHER THAN THE REGISTERED SECURITIES TO WHICH THEY RELATE. THIS
PROSPECTUS AND ANY APPLICABLE PROSPECTUS SUPPLEMENT DO NOT CONSTITUTE AN OFFER
TO SELL OR A SOLICITATION OF AN OFFER TO BUY SUCH SECURITIES IN ANY
CIRCUMSTANCES IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL.
SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION
Certain statements in this Prospectus and any Prospectus Supplement, and in
the documents incorporated herein and therein by reference, constitute
"forward-looking statements" within the meaning of Section 27A of the Securities
Act and Section 2B of the Exchange Act. For this purpose, any statements
contained in this Prospectus and any Prospectus Supplement, or incorporated
herein or therein by reference, that are not statements of historical fact may
be deemed to be forward-looking statements. Without limiting the foregoing, the
words "believes," "plans," "expects" and similar expressions are intended to
identify forward-looking statements. There are a number of important factors
that could cause the results of the Company to differ materially from those
indicated by such forward-looking statements. These factors include those set
forth under the heading "Item 7. Management's Discussion and Analysis of
Financial Condition and Results of Operations -- Certain Factors That May Affect
Future Results" in the Form 10-K and those set forth in "Risk Factors" herein.
-3-
<PAGE> 6
THE COMPANY
Hybridon, Inc. ("Hybridon" or the "Company") is a leader in the discovery
and development of novel genetic medicines based primarily on antisense
technology. Antisense technology involves the use of synthetic segments of DNA
(oligonucleotides) constructed through rational drug design to interact at the
genetic level with target messenger RNA, which codes for the production of
proteins. In contrast to traditional drugs, which are designed to interact with
protein molecules associated with diseases, antisense drugs work at the genetic
level to interrupt the process by which disease-causing proteins are produced.
Drugs based on antisense technology may have broader applicability, greater
efficacy and fewer side effects than conventional drugs because antisense
compounds are designed to intervene early in the disease process at the genetic
level and in a highly specific fashion.
Hybridon, Inc. was incorporated in Delaware in May 1989. The Company's
principal executive offices are located at 620 Memorial Drive, Cambridge,
Massachusetts 02139 and its telephone number is (617) 528- 7000.
RISK FACTORS
The Shares offered hereby involve a high degree of risk. The following risk
factors, together with the factors set forth under the heading "Item 7.
Management's Discussion and Analysis of Financial Condition and Results of
Operations--Certain Factors That May Affect Future Results" in the Form 10-K,
should be considered carefully in addition to the other information included or
incorporated by reference in this Prospectus or in any Prospectus Supplement
before purchasing the Shares offered hereby and thereby.
POSSIBLE VOLATILITY OF SHARE PRICE
Investors should be aware that market prices for securities of companies
such as Hybridon are highly volatile. Factors such as fluctuations in the
Company's operating results, announcements of technological innovations or new
commercial therapeutic products by the Company or its competitors, governmental
regulation, developments in patent or other proprietary rights, public concern
as to the safety of drugs developed by the Company and general market conditions
may have a significant effect on the market price of the Company's Common Stock.
ANTITAKEOVER PROVISIONS
The Company's Restated Certificate of Incorporation (the "Restated
Certificate") requires that any action required or permitted to be taken by
stockholders of the Company must be effected at a duly called annual or special
meeting of stockholders and may not be effected by any consent in writing, and
will require reasonable advance notice by a stockholder of a proposal or
director nomination which such stockholder desires to present at any annual or
special meeting of stockholders. Special meetings of stockholders may be called
only by the Chief Executive Officer or, if none, the President of the Company or
by the Board of Directors. The Restated Certificate provides for a classified
Board of Directors, and members of the Board of Directors may be removed only
for cause upon the affirmative vote of holders of at least two-thirds of the
shares of capital stock of the Company entitled to vote. Moreover, the Board of
Directors has the authority, without further action by the stockholders, to fix
the rights and preferences of, and issue shares of, Preferred Stock.
In addition to these provisions of the Restated Certificate, the terms of
the Company's 9% Convertible Subordinated Notes due 2004 issued in the aggregate
original principal amount of $50.0 million (the "Notes") require the Company,
upon a change of control (as defined) of the Company, to offer to repurchase the
Notes at a repurchase price equal to 150% of the principal amount thereof, plus
accrued and unpaid interest to the date of repurchase. There can be no assurance
that the Company
-4-
<PAGE> 7
would have sufficient financial resources available to satisfy all of its
obligations under the Notes in the event of a change of control. The Company's
failure to purchase the Notes would result in a default under the indenture (the
"Indenture") dated March 26, 1997 between the Company and State Street Bank and
Trust Company under which the Notes were issued, which could have adverse
consequences for the Company.
The foregoing provision of the Notes, together with the provisions of the
Restated Certificate described above and other provisions of the Restated
Certificate, may have the effect of deterring hostile takeovers or delaying or
preventing changes in control or management of the Company, including
transactions in which stockholders might otherwise receive a premium for their
shares over then current market prices. In addition, these provisions may limit
the ability of stockholders to approve transactions that they may deem to be in
their best interests.
NO DIVIDENDS ANTICIPATED IN FUTURE
The Company has not paid any cash dividends on its Common Stock since its
inception and does not anticipate paying any cash dividends on its Common Stock
in the future. Declaration of dividends on the Common Stock will depend upon,
among other things, future earnings, the operating and financial condition of
the Company, its capital requirements and general business conditions. In
addition, the Indenture limits the Company's ability to pay dividends or make
other distributions on its Common Stock, and the Company is currently prohibited
from paying cash dividends under a credit facility with a commercial bank.
USE OF PROCEEDS
Except as otherwise described in any applicable Prospectus Supplement, the
net proceeds to Hybridon from the sale of the Shares offered hereby will be used
for general corporate purposes, primarily research and product development
activities, including costs of preparing Investigational New Drug applications
and conducting preclinical studies and clinical trials, and for the equipping of
facilities. Pending application of the proceeds of the offering, the Company
intends to invest the net proceeds of the offering in short-term,
investment-grade, U.S. dollar denominated, interest bearing instruments.
The amounts actually expended by the Company and the purposes of such
expenditures may vary significantly depending upon numerous factors, including
the progress of the Company's research, drug discovery and development programs,
the results of preclinical studies and clinical trials, the timing of regulatory
approvals, technological advances, determinations as to the commercial potential
of the Company's compounds and the status of competitive products. In addition,
expenditures will also depend upon the establishment of collaborative research
arrangements with other companies, the availability of other financing and other
factors.
-5-
<PAGE> 8
PLAN OF DISTRIBUTION
The Shares offered hereby may be sold by Hybridon on a negotiated or
competitive bid basis through underwriting syndicates represented by managing
underwriters or by underwriters without a syndicate, dealers or agents
designated from time to time, or directly to other purchasers. The distribution
of the Shares offered hereby may be effected from time to time in one or more
transactions at a fixed price or prices, which may be changed, at market prices
prevailing at the time of sale, at prices related to such prevailing market
prices or at negotiated prices. To the extent required, any Prospectus
Supplement with respect to the Shares will set forth the terms of the offering
and the proceeds to the Company from the sale thereof, any underwriting
discounts and other items of price, and any discounts or concessions allowed or
reallowed or paid to dealers. Any public offering price and any discounts or
concessions allowed or reallowed or paid to dealers may be changed from time to
time.
If underwriters are utilized, the Shares being sold to them will be
acquired by the underwriters for their own account and may be resold from time
to time in one or more transactions, including negotiated transactions, at a
fixed public offering price, or at varying prices determined at the time of
sale. The Shares may be offered to the public either through underwriting
syndicates represented by one or more managing underwriters or directly by one
or more firms acting as underwriters. To the extent required, the underwriter or
underwriters with respect to the Shares being offered by Hybridon will be named
in the Prospectus Supplement relating to such offering and, if an underwriting
syndicate is used, the managing underwriter or underwriters will be set forth on
the cover page of such Prospectus Supplement. Any underwriting agreement will
provide that the obligations of the underwriters are subject to certain
conditions precedent.
If a dealer is utilized in the sale of the Shares, Hybridon will sell the
Common Stock to the dealer as principal. The dealer may then resell the Common
Stock to the public at varying prices to be determined by the dealer at the time
of sale. To the extent required, any dealer involved in the offer or sale of the
Shares in respect of which this Prospectus is delivered will be set forth in the
Prospectus Supplement.
The Shares may be sold directly by Hybridon or through agents designated by
Hybridon from time to time. To the extent required, any agent involved in the
offer or sale of the Shares in respect of which this Prospectus is delivered
will be set forth in the Prospectus Supplement. Unless otherwise indicated in
the Prospectus Supplement, any such agent will be acting on a best efforts basis
for the period of its appointment.
Any underwriters, dealers and agents that participate in the distribution
of the Common Stock may be deemed to be underwriters as the term is defined in
the Securities Act of 1933, as amended (the "Securities Act"), and any discounts
or commissions received by them from Hybridon and any profits on the resale of
the Common Stock by them may be deemed to be underwriting discounts and
commissions under the Securities Act. Underwriters, dealers and agents may be
entitled, under agreements that may be entered into with Hybridon, to
indemnification against or to contribution toward certain civil liabilities,
including liabilities under the Securities Act, or to contribution with respect
to payments that the underwriters, dealers or agents may be required to make in
respect of such liabilities.
Underwriters, dealers and agents may engage in other transactions with or
perform other services for Hybridon. To the extent required, any such
relationships will be set forth in a Prospectus Supplement.
-6-
<PAGE> 9
LEGAL MATTERS
The validity of the Shares offered hereby will be passed upon for the
Company by Hale and Dorr LLP, a limited liability partnership including
professional corporations, 60 State Street, Boston, Massachusetts 02109.
Attorneys in the law firm of Hale and Dorr LLP beneficially own an aggregate of
32,077 shares of Common Stock (including shares issuable upon exercise of stock
options).
EXPERTS
The consolidated financial statements of the Company as of December 31,
1995 and 1996 and for each of the three years in the period ended December 31,
1996 incorporated in this Prospectus and elsewhere in the Registration Statement
by reference from the Form 10-K, have been audited by Arthur Andersen LLP,
independent public accountants, as indicated in their report with respect
thereto, and are incorporated by reference herein in reliance upon the
authority of said firm as experts in giving said report.
-7-
<PAGE> 10
=========================================== ===================================
NO DEALER, SALESPERSON OR OTHER PERSON
HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION
OR TO MAKE ANY REPRESENTATIONS OTHER THAN
THOSE CONTAINED OR INCORPORATED BY REFERENCE HYBRIDON, INC.
IN THIS PROSPECTUS OR IN ANY APPLICABLE
PROSPECTUS SUPPLEMENT AND, IF GIVEN OR MADE,
SUCH INFORMATION OR REPRESENTATIONS MUST NOT
BE RELIED UPON AS HAVING BEEN AUTHORIZED BY
THE COMPANY. THIS PROSPECTUS AND ANY APPLICABLE 5,000,000 SHARES
PROSPECTUS SUPPLEMENT DO NOT CONSTITUTE AN COMMON STOCK
OFFER TO SELL OR A SOLICITATION OF ANY OFFER TO
BUY TO ANY PERSON IN ANY JURISDICTION IN WHICH
SUCH OFFER OR SOLICITATION OF AN OFFER OR
SOLICITATION WOULD BE UNLAWFUL. NEITHER THE
DELIVERY OF THIS PROSPECTUS OR ANY APPLICABLE
PROSPECTUS SUPPLEMENT NOR ANY OFFER OR SALE
HEREUNDER AND THEREUNDER SHALL, UNDER ANY
CIRCUMSTANCES, CREATE ANY IMPLICATION THAT
THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE
COMPANY SINCE THE DATE HEREOF AND THEREOF OR
THAT THE INFORMATION CONTAINED HEREIN AND
THEREIN IS CORRECT AS OF ANY DATE HEREOF AND
THEREOF.
-------------------
---------------
PROSPECTUS
TABLE OF CONTENTS
-------------------
PAGE
----
Available Information.................. 2
Incorporation of Certain Documents
By Reference........................ 2
Special Note Regarding Forward-Looking
Information.......................... 3
The Company............................ 4
Risk Factors........................... 4
Use of Proceeds........................ 5
Plan of Distribution................... 6 June ___, 1997
Legal Matters.......................... 7
Experts................................ 7
=========================================== ===================================
<PAGE> 11
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The following table sets forth the various expenses to be incurred in
connection with the sale and distribution of the securities being registered
hereby, all of which will be borne by the Registrant. All amounts shown are
estimates except the Securities and Exchange Commission registration fee.
<TABLE>
<S> <C>
Filing Fee - Securities and Exchange Commission $ 9,849
Legal fees and expenses................................ $ 40,000
Accounting fees and expenses........................... $ 10,000
Printing expenses...................................... $ 10,000
Nasdaq National Market Listing Fee..................... $ 17,500
Miscellaneous expenses................................. $ 20,000
--------
Total Expenses...................................... $107,349
========
</TABLE>
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Article EIGHTH of the Registrant's Restated Certificate of Incorporation
provides that no director of the Registrant shall be personally liable for any
monetary damages for any breach of fiduciary duty as a director, except to the
extent that the Delaware General Corporation law prohibits the elimination or
limitation of liability of directors for breach of fiduciary duty.
Article NINTH of the Registrant's Restated Certificate of Incorporation
provides that a director or officer of the Registrant (a) shall be indemnified
by the Registrant against all expenses (including attorneys' fees), judgments,
fines and amounts paid in settlement incurred in connection with any litigation
or other legal proceeding (other than an action by or in the right of the
Registrant) brought against him by virtue of his position as a director or
officer of the Registrant if he acted in good faith and in a manner he
reasonably believed to be in, or not opposed to, the best interests of the
Registrant, and, with respect to any criminal action or proceeding, had no
reasonable cause to believe his conduct was unlawful and (b) shall be
indemnified by the Registrant against all expenses (including attorneys' fees)
and amounts paid in settlement incurred in connection with any action by or in
the right of the Registrant brought against him by virtue of his position as a
director or officer of the Registrant if he acted in good faith and in a manner
he reasonably believed to be in, or not opposed to, the best interests of the
Registrant, except that no indemnification shall be made with respect to any
matter as to which such person shall have been adjudged to be liable to the
Registrant, unless a court determines that, despite such adjudication but in
view of all of the circumstances, he is entitled to indemnification of such
expenses. Notwithstanding the foregoing, to the extent that a director or
officer has been successful, on the merits or otherwise, including, without
limitation, the dismissal of an action without prejudice, he is required to be
indemnified by the Registrant against all expenses (including attorneys' fees)
incurred in connection therewith. Expenses shall be advanced to a Director or
officer at his request, provided that he undertakes to repay the amount advanced
if it is ultimately determined that he is not entitled to indemnification for
such expenses.
Indemnification is required to be made unless the Registrant determines
that the applicable standard of conduct required for indemnification has not
been met. In the event of a determination by the Registrant that the director or
officer did not meet the applicable standard of conduct required for
indemnification, or if
II-1
<PAGE> 12
the Registrant fails to make an indemnification payment within 60 days after
such payment is claimed by such person, such person is permitted to petition the
court to make an independent determination as to whether such person is entitled
to indemnification. As a condition precedent to the right of indemnification,
the director or officer must give the Registrant notice of the action for which
indemnity is sought and the Registrant has the right to participate in such
action or assume the defense thereof.
Article NINTH of the Registrant's Restated Certificate of Incorporation
further provides that the indemnification provided therein is not exclusive, and
provides that in the event that the Delaware General Corporation Law is amended
to expand the indemnification permitted to directors or officers the Registrant
must indemnify those persons to the full extent permitted by such law as so
amended.
Section 145 of the Delaware General Corporation Law provides that a
corporation has the power to indemnify a director, officer, employee or agent of
the corporation and certain other persons serving at the request of the
corporation in related capacities against amounts paid and expenses incurred in
connection with an action or proceeding to which he is or is threatened to be
made a party by reason of such position, if such person shall have acted in good
faith and in a manner he reasonably believed to be in or not opposed to the best
interests of the corporation, and, in any criminal proceeding, if such person
had no reasonable cause to believe his conduct was unlawful; provided that, in
the case of actions brought by or in the right of the corporation, no
indemnification shall be made with respect to any matter as to which such person
shall have been adjudged to be liable to the corporation unless and only to the
extent that the adjudicating court determines that such indemnification is
proper under the circumstances.
The Registrant is a party to indemnification agreements E. Andrews
Grinstead III, the Company's Chairman, President and Chief Executive Officer,
and Anthony J. Payne, the Company's Senior Vice President of Finance and
Administration and Chief Financial Officer. Such agreements provide that either
of such individuals shall be indemnified by the Registrant (a) against all
expenses (as defined in the agreements), judgments, fines, penalties and amounts
paid in settlement actually and reasonably incurred in connection with any legal
proceeding (other than one brought by or on behalf of the Registrant) if such
individual acted in good faith and in a manner which he reasonably believed to
be in, or not opposed to, the best interests of the Registrant, and with respect
to any criminal proceeding, had no reasonable cause to believe that his conduct
was unlawful and (b) against all expenses and amounts paid in settlement
actually and reasonably incurred in connection with a legal proceeding brought
by or on behalf of the Registrant if such individual acted in good faith and in
a manner which he reasonably believed to be in, or not opposed to, the best
interests of the Registrant, except that no indemnification shall be made in
respect of any claim, issue or matter as to which such individual has been
adjudged to be liable. If, with respect to such proceedings, such individual is
successful on the merits or otherwise, such individual shall be reimbursed for
all expenses. These individuals are required to provide notice to the Registrant
of any threatened or pending litigation, and the Registrant has the right to
participate in such action or assume the defense thereof.
II-2
<PAGE> 13
ITEM 16. LIST OF EXHIBITS.
1* Form of Underwriting Agreement for Common Stock.
3.1** Restated Certificate of Incorporation of the Registrant.
3.2** Amended and Restated By-Laws of the Registrant.
4*** Specimen Certificate for shares of Common Stock, $.001 par value per
share, of the Registrant.
5 Opinion of Hale and Dorr LLP.
23.1 Consent of Hale and Dorr LLP, included in Exhibit 5 filed herewith.
23.2 Consent of Arthur Andersen LLP.
23.3 Consent of Banner & Witcoff, Ltd.
24 Power of Attorney (See page II-5 of this Registration Statement).
- ------------
* To be filed by amendment or as an exhibit to a document to be incorporated
by reference herein in connection with an offering of the offered
securities.
** Incorporated by reference to Exhibits to the Registrant's Annual Report on
Form 10-K for the year ended December 31, 1995.
*** Incorporated by reference to Exhibits to the Registrant's Registration
Statement on Form S-1 (File No. 33-99024).
ITEM 17. UNDERTAKINGS.
The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of
the Securities Act of 1933, as amended (the "Securities Act");
(ii) To reflect in the prospectus any facts or events arising
after the effective date of this Registration Statement (or the most
recent post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth in
this Registration Statement. Notwithstanding the foregoing, any increase
or decrease in the volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price represent no more than 20% effective change in the
maximum aggregate offering price set forth in the "Calculation of
Registration Fee" table in the Registration Statement; and
(iii) To include any material information with respect to the
plan of distribution not previously disclosed in this Registration
Statement or any material change to such information in this Registration
Statement.
II-3
<PAGE> 14
(2) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of
the offering.
The Registrant hereby undertakes that, for purposes of determining any
liability under the Securities Act, each filing of the Registrant's annual
report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where
applicable, each filing of an employee benefit plan's annual report pursuant to
Section 15(d) of the Exchange Act) that is incorporated by reference in this
Registration Statement shall be deemed to be a new registration statement
relating to the securities offered therein and the offering of such securities
at the time shall be deemed to be the initial bona fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the indemnification provisions described herein, or
otherwise, the Registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the
payment by the Registrant of expenses incurred or paid by a director, officer or
controlling person of the Registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the Registrant will, unless
in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue.
The undersigned Registrant hereby undertakes that:
(1) For purposes of determining any liability under the Securities
Act, the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h)
under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective.
(2) For the purpose of determining any liability under the Securities
Act, each post-effective amendment that contains a form of prospectus shall be
deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
II-4
<PAGE> 15
SIGNATURES
Pursuant to the requirements of the Securities Act, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-3 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 3rd
day of June, 1997.
HYBRIDON, INC.
By: /s/ E. Andrews Grinstead, III
-------------------------------------
E. Andrews Grinstead, III
Chairman of the Board, President and
Chief Executive Officer
POWER OF ATTORNEY
We, the undersigned officers and directors of Hybridon, Inc., hereby
severally constitute E. Andrews Grinstead, III, Anthony J. Payne and Douglas J.
Jensen, and each of them singly, our true and lawful attorneys with full power
to any of them, and to each of then singly, to sign for us and in our names in
the capacities indicated below the Registration Statement on Form S-3 filed
herewith and any and all pre-effective and post-effective amendments to said
Registration Statement (including without limitation any subsequent Registration
Statement for the same offering which may be filed under Rule 462 of the
Securities Act) and generally to do all such things in our name and behalf in
our capacities as officers and directors to enable Hybridon, Inc. to comply with
the provisions of the Securities Act and all requirements of the Securities and
Exchange Commission, hereby ratifying and confirming our signatures as they may
be signed by our said attorneys, or any of them, to said Registration Statement
and any and all amendments thereto.
Pursuant to the requirements of the Securities Act, this Registration
Statement has been signed by the following persons in the capacities and on the
date indicated.
Signature Title Date
--------- ----- ----
/s/ E. Andrews Grinstead, III Chairman of the Board, President June 3, 1997
- -------------------------------- and Chief Executive Officer and
E. Andrews Grinstead, III Director (Principal Executive
Officer)
/s/ Anthony J. Payne Senior Vice President of Finance June 3, 1997
- -------------------------------- Administration, Treasurer,
Anthony J. Payne Secretary and Chief Financial
Officer (Principal Financial and
Accounting Officer)
/s/ Sudhir Agrawal Director June 3, 1997
- --------------------------------
Sudhir Agrawal
II-5
<PAGE> 16
/s/ J. Robert Buchanan Director June 1, 1997
- ----------------------------
J. Robert Buchanan
/s/ Mohamed El-Khereiji Director June 1, 1997
- ----------------------------
Mohamed El-Khereiji
/s/ Youssef El-Zein Director June 2, 1997
- ----------------------------
Youssef El-Zein
/s/ Nasser Menhall Director June 1, 1997
- ----------------------------
Nasser Menhall
/s/ Jerry A. Weisbach Director June 1, 1997
- ----------------------------
Jerry A. Weisbach
/s/ James B. Wyngaarden Director June 1, 1997
- ----------------------------
James B. Wyngaarden
/s/ Paul C. Zamecnik Director June 3, 1997
- ----------------------------
Paul C. Zamecnik
II-6
<PAGE> 17
INDEX TO EXHIBITS
1* Form of Underwriting Agreement for Common Stock.
3.1** Restated Certificate of Incorporation of the Registrant.
3.2** Amended and Restated By-Laws of the Registrant.
4*** Specimen Certificate for shares of Common Stock, $.001 par value per
share, of the Registrant.
5 Opinion of Hale and Dorr LLP.
23.1 Consent of Hale and Dorr LLP, included in Exhibit 5 filed herewith.
23.2 Consent of Arthur Andersen LLP.
23.3 Consent of Banner & Witcoff, Ltd.
24 Power of Attorney (See page II-5 of this Registration Statement).
- ------------
* To be filed by amendment or as an exhibit to a document to be incorporated
by reference herein in connection with an offering of the offered
securities.
** Incorporated by reference to Exhibits to the Registrant's Annual Report on
Form 10-K for the year ended December 31, 1995.
*** Incorporated by reference to Exhibits to the Registrant's Registration
Statement on Form S-1 (File No. 33-99024).
<PAGE> 1
Exhibit 5
HALE AND DORR LLP
COUNSELLORS AT LAW
60 STATE STREET, BOSTON, MASSACHUSETTS 021O9
617-526-6OOO o FAX 617-526-5OOO
June 3, 1997
Hybridon, Inc.
620 Memorial Drive
Cambridge, MA 02139
Ladies and Gentlemen:
This opinion is furnished to Hybridon, Inc., a Delaware corporation (the
"Company"), in connection with a Registration Statement on Form S-3 (the
"Registration Statement") filed today with the Securities and Exchange
Commission (the "Commission") under the Securities Act of 1933, as amended (the
"Securities Act"), relating to the offer and sale from time to time of up to
5,000,000 shares (the "Shares") of the Company's Common Stock, $.001 par value
per share ("Common Stock").
We have examined signed copies of the Registration Statement and all
exhibits thereto, all as filed with the Commission. We have also examined and
relied upon the original or copies of minutes of meetings of the stockholders
and Board of Directors (the "Board") of the Company, a copy of the By-Laws of
the Company, as amended, and a copy of the Restated Certificate of Incorporation
of the Company, as amended.
In our examination of the foregoing documents, we have assumed (i) the
genuineness of all signatures and the authenticity of all documents submitted to
us as originals, (ii) the conformity to the originals of all documents submitted
to us as certified, facsimile or photostatic copies, and (iii) the authenticity
of the originals of such latter documents.
In rendering this opinion, we have assumed that (i) the Registration
Statement and any amendments thereto (including post-effective amendments) will
have become effective and comply with all applicable laws and regulations; (ii)
the Registration Statement will be effective and will comply with all applicable
laws and regulations at the time the Shares are offered or issued as
contemplated by the Registration Statement; (iii) a Prospectus Supplement will
have been prepared and filed with the Commission describing the Shares offered
thereby and will comply with all applicable laws and regulations; (iv) all
Shares will be issued and sold in compliance with applicable federal and state
securities laws and regulations and in the manner stated in the Registration
Statement and the appropriate Prospectus Supplement thereto (including the
receipt of consideration therefor by the Company); and (v) a definitive
purchase, underwriting or similar agreement with respect to any Shares offered
or issued will have been duly authorized and validly executed and delivered by
the Company and the other parties thereto.
WASHINGTON, DC BOSTON, MA LONDON, UK*
- --------------------------------------------------------------------------------
HALE AND DORR LLP INCLUDES PROFESSIONAL CORPORATIONS
*BROBECK HALE AND DORR INTERNATIONAL (AN INDEPENDENT JOINT VENTURE LAW FIRM)
<PAGE> 2
Hybridon, Inc.
June 3, 1997
Page 2
Based upon the foregoing, we are of the opinion that the Shares, when both
(i) the Board has taken all necessary corporate action to approve the issuance
of and the specific terms of the offering of the Shares and related matters and
(ii) certificates representing the Shares have been duly executed,
countersigned, registered and delivered in accordance with the applicable
definitive purchase, underwriting or similar agreement approved by the Board
upon payment of the consideration therefor (not less than the par value of the
Common Stock) provided for therein, will be duly authorized and validly issued,
fully paid and non-assessable.
Please note that we are opining only as to the matters expressly set forth
herein, and no opinion should be inferred as to any other matters.
We hereby consent to the filing of this opinion with the Commission as an
exhibit to the Registration Statement in accordance with the requirements of
Item 601(b)(5) of Regulation S-K under the Securities Act and to the use of our
name therein and in related Prospectus Supplements under the caption "Legal
Matters." In giving such consent, we do not hereby admit that we are in the
category of persons whose consent is required under Section 7 of the Securities
Act or the rules and regulations of the Commission.
It is understood that this opinion is to be used only in connection with
the offer and sale of the Shares while the Registration Statement is in effect.
Very truly yours,
/s/Hale and Dorr LLP
Hale and Dorr LLP
<PAGE> 1
Exhibit 23.2
------------
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation
by reference in this registration statement of our report dated February 21,
1997 (except with respect to the matter discussed in Note 1, as to which the
date is March 26, 1997) included in Hybridon's Form 10-K for the year ended
December 31, 1996, and to all references to our Firm included in this
registration statement.
/s/ Arthur Andersen LLP
----------------------------------
ARTHUR ANDERSEN LLP
Boston, Massachusetts
June 2, 1997
<PAGE> 1
Exhibit 23.3
------------
Law Offices
BANNER & WITCOFF, LTD.
75 State Street
Boston, Massachusetts 02109-1807
Telephone: (617) 345-9100
Facsimile: (617) 345-9111
June 3, 1997
Hybridon, Inc.
620 Memorial Drive
Cambridge, Massachusetts 02139
Re: Hybridon, Inc. - Annual Report on Form 10-K
-------------------------------------------
Dear Sirs:
Banner & Witcoff, Ltd. hereby consents to the reference to our firm under
the section "Business--Patents, Trade Secrets and Licenses" in the Hybridon,
Inc. Annual Report on Form 10-K for the year ended December 31, 1996, which is
incorporated by reference in this Registration Statement.
Yours very truly,
/s/ Leon R. Yankwich
----------------------------------
Leon R. Yankwich
